Site icon pharmaceutical daily

Quanterix Corporation Releases Operating Results for First Quarter 2019

64% Q1 revenue growth and 650 bps gross margin improvement

LEXINGTON, Mass.–(BUSINESS WIRE)–Quanterix
Corporation (NASDAQ:QTRX)
, a company digitizing biomarker analysis
to advance the science of precision health, today announced financial
results for the three months ended March 31, 2019.

“We’ve made strong progress over the past quarter, which now marks our
sixth consecutive quarter since the IPO of accelerated growth. In
addition, we are achieving important goals in neurology and now oncology
with the launch of our new SP-X™ Imaging and Detection System,” said
Kevin Hrusovsky, Chief Executive Officer, President and Chairman,
Quanterix. “There is mounting evidence supporting our Simoa technology’s
potential to transform virtually every category of medicine. The extreme
precision and sensitivity of our expanding portfolio of instruments and
platforms is fueling new insights on drug targets, disease progression
biomarkers and new opportunities for patient stratification for clinical
trials, transforming traditional approaches to drug development and
precision medicine.”

First Quarter 2019 Financial Highlights

Key financial results for the first quarter are shown below:

First Quarter 2019 Business Highlights

Conference Call

In conjunction with this announcement, Quanterix Corporation will host a
conference call on May 9, 2019, at 4:30 p.m., EDT to discuss the
Company’s financial results and business outlook. To access this call,
dial (833) 686-9351 for domestic callers, or (612) 979-9890 for
international callers. Please reference the following conference ID:
8955828.

A live webcast will be accessible on the Investors section of Quanterix’
website: http://www.quanterix.com.
The webcast will be available on the Company’s website for one year
following completion of the call.

           

Financial Highlights (in thousands)

 

Quarterly Statement of Operations

 
Q1 2019 Q1 2018
Product Revenue $9,547 $4,745
Service and other revenue 2,790 2,507
Collaboration revenue       0         269  

Total revenue

$12,337 $7,521
 
Cost of product revenue $4,248 $2,773
Cost of service revenue       2,082         1,576  

Gross profit

$6,007 $3,172
 
Research and development $3,684 $3,573
Selling, general and administrative 10,381 6,055
Stock comp expenses included in operating expenses       1,299         707  

Total operating expenses

$15,364 $10,335
 
Interest income (expense), net $21 ($24 )
Other income (expense), net       (47 )       (15 )

Loss before income tax

($9,383 ) ($7,202 )
 
Other income (expense), net       22         0  

Net loss

($9,405 ) ($7,202 )
             

Quanterix Balance Sheet

 

03/31/2019

12/31/2018

Cash and cash equivalents $33,972 $44,429
AR 7,303 6,792
Inventory 7,742 5,945
Prepaid and other       2,502         2,330
Total current assets $51,519 $59,496
 
Restricted Cash $1,019 $1,000
Property and equipment, net 8,582 2,923
Intangible assets and goodwill 3,506 3,656
Other non-current assets       550         536
Total assets $65,176 $67,611
 
Accounts payable / accrued expenses $11,039 $12,688
Deferred revenue 5,484 5,437
Current portion of long term debt 75 0
Lease incentive obligation       461         0
Total current liabilities $17,059 $18,125
 
Deferred revenue, net of current portion $431 $520
Long term debt 7,572 7,623
Lease incentive obligation, net of current portion 4,804 0
Other non-current liabilities       1,095         278
Total Liabilities $30,961 $26,546
 
Total stockholder equity       $34,215         $41,065
Total liabilities and shareholders equity $65,176 $67,611
 

About Quanterix
Quanterix is a company that’s digitizing
biomarker analysis with the goal of advancing the science of precision
health. The company’s digital health solution, Simoa, has the potential
to change the way in which healthcare is provided today by giving
researchers the ability to closely examine the continuum from health to
disease. Quanterix’ technology is designed to enable much earlier
disease detection, better prognoses and enhanced treatment methods to
improve the quality of life and longevity of the population for
generations to come. The technology is currently being used for research
applications in several therapeutic areas, including oncology,
neurology, cardiology, inflammation and infectious disease. The company
was established in 2007 and is located in Lexington, Massachusetts. For
additional Information, please visit https://www.quanterix.com.

Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,”
“plan,” “anticipate,” “estimate,” “intend” and similar expressions (as
well as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release are based on Quanterix’
expectations and assumptions as of the date of this press release. Each
of these forward-looking statements involves risks and uncertainties.
Factors that may cause Quanterix’ actual results to differ from those
expressed or implied in the forward-looking statements in this press
release are discussed in Quanterix’ filings with the U.S. Securities and
Exchange Commission, including the “Risk Factors” sections contained
therein. Except as required by law, Quanterix assumes no obligation to
update any forward-looking statements contained herein to reflect any
change in expectations, even as new information becomes available.

Contacts

Quanterix, Inc.
Amol Chaubal, CFO, 617-301-9495
achaubal@quanterix.com

PAN Communications
Lindsay Poole, 617-502-4300
quanterix@pancomm.com

Exit mobile version